BC Week In Review | Nov 30, 2018
Clinical News

Vectura discontinues asthma therapy after Phase III miss

Vectura Group plc (LSE:VEC) said it will discontinue development of VR475 after both doses of the compound missed the primary endpoint in a Phase III trial to treat severe uncontrolled asthma. Both twice-daily 0.5 and...
BC Week In Review | Jan 26, 2015
Clinical News

VR475: Phase IIb/III data

The double-blind, European Phase IIb/III Acti-AICS-001 trial in 199 asthma patients dependent on oral corticosteroids showed that VR475 with a 1 mg dose of budesonide met the primary endpoint of a greater proportion of patients...
BioCentury | Mar 31, 2014

LSP's steady hand

When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months - early stage, European drug development companies. The...
BC Extra | Mar 13, 2014
Company News

Vectura acquiring Activaero, raises L52 million in placing

Pulmonary play Vectura Group plc (LSE:VEC) is acquiring drug delivery company Activaero GmbH (Gemuenden, Germany) for EUR 130 million ($180.6 million). The amount comprises EUR 45 million ($62.5 million) up front in cash and EUR...
BC Week In Review | Jan 31, 2011
Company News

Activaero, Forest Laboratories sales and marketing update

Activaero and Forest's Forest Healthcare B.V. subsidiary will co-promote Activaero's Akita Jet inhalation system in Germany to treat bacterial infections in patients with cystic fibrosis. The partners plan to use the system to optimize high-dose...
BC Week In Review | Dec 21, 2009
Clinical News

Akita Jet regulatory update

FDA granted 510(k) clearance for Activaero's Akita Jet inhalation system, a device designed to increase deposition efficiency of inhaled therapeutics. The company said the device is being used to deliver an undisclosed therapeutic candidate that...
Items per page:
1 - 6 of 6